A
ONCT

Abingworth’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Abingworth’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,423
Closed -$5.2M – 17
2018
Q2 		$5.2M Hold
2,423
– – 2.97% 5
2018
Q1 		$6.02M Hold
2,423
– – 3.74% 4
2017
Q4 		$4.28M Hold
2,423
– – 3.1% 6
2017
Q3 		$2.78M Buy
+2,423
New +$2.18M 1.93% 11

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Abingworth's ONCT Position: Q3 2018 in Review

Abingworth sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 2,423 shares — an estimated $5.2M sold.

Abingworth first reported a position in ONCT in Q3 2017 and held it in 4 quarters. The position peaked at $6.02M in Q1 2018. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

  • Abingworth reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Abingworth sold 2,423 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $5.2M.
  • Abingworth first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2017 and held it in 4 quarters.
  • Abingworth's Oncternal Therapeutics, Inc. Common Stock position peaked at $6.02M in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Abingworth's 13F filing for Q3 2018, filed 14 Nov 2018.